Lead Product(s) : Cannabidiol
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tetra Receives FDA Orphan Drug Designation for its Ophthalmic Clinical Program
Details : Research in an experimental model of PVR has demonstrated that the synthetic cannabinoid, PPP003, can prevent this condition through activation of the type 2 cannabinoid receptor.
Product Name : PPP003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 15, 2020
Lead Product(s) : Cannabidiol
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable